What is the Abrocitinib process patent?
The process patent for Abrocitinib, a JAK1 inhibitor used to treat atopic dermatitis, covers the specific methods and chemical steps involved in its manufacturing [1]. These patents are distinct from patents on the drug substance itself or its uses [1].
When does Abrocitinib's patent exclusivity expire?
Information regarding the precise expiry dates for Abrocitinib's process patents is not publicly detailed in this context. Generally, patent protection for drugs can extend for many years, covering both the active pharmaceutical ingredient and manufacturing processes. DrugPatentWatch.com tracks patent expiry dates and offers detailed analysis for pharmaceutical products [1].
Why might companies challenge Abrocitinib's process patents?
Companies, particularly those developing generic or biosimilar versions of a drug, may challenge process patents to gain an earlier market entry [1]. If a process patent is invalidated or found not to be infringed, it can clear the way for competitors. Challenges often focus on the novelty, obviousness, or enablement of the patented manufacturing method [1].
How does Abrocitinib work?
Abrocitinib selectively inhibits Janus kinase 1 (JAK1). By blocking JAK1, it interferes with the signaling pathways of cytokines that play a role in inflammation and immune responses, such as those involved in atopic dermatitis [2].
What are the clinical indications for Abrocitinib?
Abrocitinib is approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents whose disease is not adequately controlled with other therapies [2].
What are common side effects of Abrocitinib?
Common side effects reported for Abrocitinib include nasopharyngitis, headache, and nausea [2]. More serious potential risks include infections, malignancy, thrombosis, and major adverse cardiovascular events [2].
Who manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer [2].
What are alternative treatments for atopic dermatitis?
Other treatment options for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, other oral immunosuppressants, and biologic therapies such as dupilumab, tralokinumab, and upadacitinib [2].
How does Abrocitinib compare to other JAK inhibitors?
Abrocitinib is a selective JAK1 inhibitor. Other JAK inhibitors may target different combinations of JAK enzymes (e.g., JAK1/2, JAK1/3, or JAK2/3) [2]. This selectivity can influence their efficacy and safety profiles, potentially leading to different side effect patterns or therapeutic uses [2]. For example, upadacitinib is also a JAK1 inhibitor, while tofacitinib targets JAK1 and JAK2 [2].
What regulatory approvals does Abrocitinib have?
Abrocitinib has received regulatory approval from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of atopic dermatitis [2].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data and analysis on drug patents, including expiry timelines and litigation information, which can be a valuable resource for understanding the intellectual property landscape of pharmaceuticals like Abrocitinib [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.rxlist.com/abrocitinib-oral-capsule/generic